In a recent paper published in the journal of Biotechnology, Glenmark Pharmaceuticals S.A. describes the use of the TLA technology in the analytical assessment of clonal derivation of cell populations.

In the paper entitled '’Analytical assessment of clonal derivation of eukaryotic/CHO cell populations’’, Glenmark illustrates how TLA and next generation sequencing (NGS) can determine transgene integration sites and plasmid-plasmid fusions resulting from the concatemerisation of multiple (partial) plasmid copies.

In this manner, unique genetic features were identified that were used to demonstrate the clonal derivation of CHO cell lines.

For more information, review the paper by clicking the button below.